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Inhalation characteristics of asthma patients,
COPD patients and healthy volunteers with the
Spiromax® and Turbuhaler® devices: a
randomised, cross-over study
Wahida Azouz1, Philip Chetcuti2, Harold Hosker3, Dinesh Saralaya4 and Henry Chrystyn5*
Abstract
Background: Spiromax® is a novel dry-powder inhaler containing formulations of budesonide plus formoterol (BF).
The device is intended to provide dose equivalence with enhanced user-friendliness compared to BF Turbuhaler® in
asthma and chronic obstructive pulmonary disease (COPD). The present study was performed to compare inhalation
parameters with empty versions of the two devices, and to investigate the effects of enhanced training designed to
encourage faster inhalation.
Methods: This randomised, open-label, cross-over study included children with asthma (n = 23), adolescents with
asthma (n = 27), adults with asthma (n = 50), adults with COPD (n = 50) and healthy adult volunteers (n = 50). Inhalation
manoeuvres were recorded with each device after training with the patient information leaflet (PIL) and after enhanced
training using an In-Check Dial device.
Results: After PIL training, peak inspiratory flow (PIF), maximum change in pressure (∆P) and the inhalation volume (IV)
were significantly higher with Spiromax than with the Turbuhaler device (p values were at least <0.05 in all patient
groups). After enhanced training, numerically or significantly higher values for PIF, ∆P, IV and acceleration remained
with Spiromax versus Turbuhaler, except for ∆P in COPD patients. After PIL training, one adult asthma patient and one
COPD patient inhaled <30 L/min through the Spiromax compared to one adult asthma patient and five COPD patients
with the Turbuhaler. All patients achieved PIF values of at least 30 L/min after enhanced training.
Conclusions: The two inhalers have similar resistance so inhalation flows and pressure changes would be expected to
be similar. The higher flow-related values noted for Spiromax versus Turbuhaler after PIL training suggest that Spiromax
might have human factor advantages in real-world use. After enhanced training, the flow-related differences between
devices persisted; increased flow rates were achieved with both devices, and all patients achieved the minimal flow
required for adequate drug delivery. Enhanced training could be useful, especially in COPD patients.
Keywords: Adolescent, Asthma, Child, Chronic obstructive pulmonary disease, Inhalation therapy, Inhalation
manoeuvre characteristics, Spiromax, Training activities, Turbuhaler
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Background
Most patients with asthma or chronic obstructive pul-
monary disease (COPD) require drug treatment with
inhalation the major route of administration. The ma-
jority of asthma and COPD patients use their pres-
surised metered-dose inhaler (pMDI) incorrectly [1,2].
Major reasons for this are failure by patients to co-
ordinate actuation with inhalation and failure to use a
slow and deep inhalation [1,3,4]. Dry powder inhalers
(DPIs) were developed with the intention of preventing
errors in the co-ordination of actuation and inhalation.
With a DPI, the act of inhalation de-aggregates (‘breaks
up’) and releases the metered dose of drug, thereby re-
moving the need for a patient to coordinate actuation
with inhalation.
A potential drawback of DPIs is their dependency
upon the patient’s inspiratory effort for delivering the
correct dose of drug to the lungs [5,6]. Drug dose, par-
ticle size distribution and, ultimately, clinical effective-
ness are dependent not only on peak inspiratory flow
(PIF), but also acceleration rate (ACC) and inhalation
time (Ti) [7-9]. This is related to the fact that drug parti-
cles are de-aggregated (a process dependent on airflow
through the device [5]) before emission from the device
to ensure they are small enough to reach the site of ac-
tion in the small airways.
The ERS/ISAM task force has recommended that the
inhalation manoeuvre when using a DPI should be
forceful from the beginning and that inhalation should
be continued for as long as is comfortable [10]. Disease
severity may affect a patient’s ability to perform an inhal-
ation manoeuvre with sufficient force to de-aggregate
the dose, potentially jeopardising the effectiveness of in-
haled medication [1,11]. Differences between devices are
apparent regarding the inhalation rates that patients can
achieve, which is controlled by the internal resistance to
airflow inside the inhalation channel of the device [12].
This may alter the effectiveness of treatment that a pa-
tient can obtain. However, patient counselling has been
shown to increase the proportion of patients achieving
adequate inhalation flow rates [13,14]. Moreover, results
from studies of the Turbuhaler® DPI have shown that
most patients are able to inhale using flow rates neces-
sary for effective treatment [15-17].
The Spiromax® device (Figure 1) is a novel DPI. DuoResp®
Spiromax (budesonide plus formoterol [BF] Spiromax)
is approved for use in the European Union for treatment
of adults (≥18 years old) with asthma and for patients
with COPD for whom an inhaled corticosteroid/long-
acting β2 agonist (ICS/LABA) combination is indicated
[18]. The formulations of BF in BF Spiromax provide
comparable quality and are equivalent to BF (Symbicort®)
Turbuhaler at equivalent strengths [18]. Regulatory ap-
proval of Spiromax was dependent on demonstration of
equivalence as opposed to superiority versus Turbuhaler,
with respect to delivered dose and pharmacokinetics/
pharmacodynamics.
The present study was performed to investigate PIF
and related inhalation parameters of patients with stable
asthma, patients with stable COPD and healthy adult
volunteers when using empty Spiromax and empty
Turbuhaler devices [19-22]. The effect of enhanced
training on inhalation parameters was also assessed.
Methods
This was a randomised, open-label, cross-over study in-
volving five groups of participants: children with
asthma, adolescents with asthma, adults with asthma,
adults with COPD and healthy adult volunteers. The
study was conducted at four centres in the United King-
dom, with recruitment from 1 November 2010 until 2
March 2011. Local research ethics committee approval
was obtained (Bradford Research Ethics Committee 09/
H1302/64), in addition to Research and Development
approval from each participating centre. The study was
conducted in accordance with good clinical practice and
the declaration of Helsinki. All study participants, and
parents/guardians of participants aged ≤17 years, pro-
vided signed informed consent.
Figure 1 Spiromax device. Copyright of Teva UK Limited.
Reproduced with permission.
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Inclusion/exclusion criteria
One hundred asthma patients were recruited as follows:
children (age range 6–11 years, n = 23); adolescents (age
range 12–17 years, n = 27); adults (age range 18–45
years, n = 50). Inclusion criteria for these patients were:
stable asthma with no other respiratory conditions, and
use of inhaled asthma medication for ≥4 weeks before
study enrolment. Patients with an asthma exacerbation
or who required oral prednisolone therapy during the
4 weeks preceding enrolment were excluded. Adult
COPD patients (age >50 years, n = 50) were recruited,
provided they had been taking inhaled COPD medica-
tion for ≥4 weeks before study enrolment. Exclusion cri-
teria for COPD patients were asthma or other clinically
relevant pulmonary disease, and an exacerbation of
COPD or oral prednisolone therapy during the 4 weeks
before enrolment.
Study design, PIL training and enhanced training
Participants completed the study during a single clinic
visit (Figure 2). Demographic data were recorded and
lung function (peak expiratory flow rate [PEFR], forced
expiratory volume in 1 second [FEV1]) was assessed by
spirometry. Disease status was assessed in patients with
asthma or COPD using the Asthma Control Questionnaire
(ACQ; six domains, each with a scale from 0 [minimal im-
pairment] [23] to 6 [severe impairment]) or Baseline Dys-
pnoea Index (BDI; three categories, each with a symptom
severity scale from grade 1 [minimal impairment] to grade
5 [severe impairment]), respectively.
Both the Spiromax (Teva Pharmaceuticals) and the
Turbuhaler (AstraZeneca) were provided by the manufac-
turers as empty devices, containing neither active drug
nor powder vehicle but otherwise unmodified.
Randomisation was performed to determine which of
the two devices would be used first. Training to use each
DPI was provided verbally by a highly trained researcher,
with instructions as per the patient information leaflet
(obtained from the manufacturers of both devices). Two
consecutive inhalation manoeuvres were then performed
with each device.
Study participants subsequently underwent enhanced
training using an In-Check Dial™ (Clement Clarke Inter-
national) [5] with the device set to the resistance of a
Turbuhaler. This training was provided by a highly
trained researcher, who also made the inhalation manoeuvre
measurements. Participants were shown their PIF and en-
couraged to improve it by inhaling more quickly, parti-
cularly from the start of their inhalation. Inhalation
parameters for two manoeuvres performed using the fas-
ter inhalation technique were then measured in the same
way as before enhanced training.
Measurement of inhalation characteristics
A probe (ensuring an airtight seal) was placed into the
inhalation channel of each inhaler distal from the open-
ing of the mouthpiece. The probe was connected to
PR3202 low differential pressure sensors (Applied Mea-
surements Ltd, Reading, UK). The resistance of the DPI
was measured before and after the insertion of the probe
to ensure no changes and that an airtight seal was
present. During each inhalation, the change in pressure
(in mbar) with time (in milliseconds) that occurred in
the inhalation channel of the device, was downloaded
into an EXCEL spreadsheet.
The pressure changes were converted to inhalation
flow as recommended by Clark and Hollingworth [6].
From the pressure-time readings and the corresponding
inhalation flow readings the following parameters were
obtained: PIF (in L min-1), the time to PIF (Tmax), the
maximum pressure change that occurred inside the DPI
(∆P; in kPa), the initial acceleration of the inhalation
flow (ACCEL; in kPa sec-1), the inhalation volume (IV;
in litres), and the duration of the inhalation (Ti; in sec-
onds). The internal resistance of each device was mea-
sured using the technique of Clark and Hollingworth.
Statistical analysis
For each pair of manoeuvres, the profile with the highest
PIF was selected for analysis. Descriptive statistics were
calculated for each parameter, and results are presented
as mean and standard deviation. The percentage















Figure 2 Study design.
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improvement in each inhalation parameter following
training was calculated for each subject; the mean per-
centage improvement and standard deviation are
presented.
The paired t-test was used to determine whether there
were statistically significant differences between the Spiro-
max and Turbuhaler devices, both pre- and post-training.
The paired t-test was also used to examine whether differ-
ences between values post- and pre-training were statisti-
cally significant. The statistical analysis was performed
using SPSS version 17/18.
Results
Study participants
Demographics and baseline characteristics of the study
participants are shown in Table 1. None of these individ-
uals withdrew prematurely before completing the study.
The mean ACQ score was 1.62 (standard deviation, SD,
0.95) for children with asthma (aged 6–11 years), 1.66
(0.97) for adolescents with asthma and 1.85 (0.90) for
adults with asthma. Seven percent of all of the asthma
patients had well controlled disease (ACQ score <0.7),
48% had partly controlled asthma (ACQ score 0.7–1.5)
and 45% had poorly controlled disease (ACQ score >1.5).
The majority of COPD patients had BDI grade 3 (18 sub-
jects, 36%) or grade 4 (16 subjects, 32%); the remainder
had grade 2 (n = 8) or grade 5 (n = 8).
Asthma or COPD medication use reported at start of
study
Salbutamol was taken by >90% of the patients with
asthma and by 82% of those with COPD. Percentages of
salbutamol recipients receiving the drug via an MDI
(with or without a spacer) were as follows: 100% of the
children with asthma, 85%; of the adolescents with
asthma, 80%; of the adults with asthma, and 60% of the
80%; COPD patients.
Other medications used by asthma patients were
Seretide™ Accuhaler™ (34.8-52%) and Symbicort Turbuhaler
(30.4-51.9%). Of the COPD patients, 74% were prescribed
salbutamol.
Device characteristics
The internal resistance of the empty Spiromax device
was 0.100 (cmH20)½ (l/min)-1 (equivalent to 0.0313
kPa½ (l/min)-1), which is similar to the resistance of the
commercially available Spiromax device. The internal re-
sistance of the Turbuhaler device used was 0.107
(cmH20)½ (l/min)-1 (equivalent to 0.0355 kPa½ (l/min)-1)
and this is similar to commercially available Symbicort®
Turbuhaler [24].
Inhalation parameters after standard PIL training
PIF, maximum change in pressure (∆P) and inhalation
volume (IV) were significantly higher with Spiromax
than with the Turbuhaler device (Table 2). Differences
between the two inhalers in PIF were highly significant
in all five study groups (p ≤ 0.0001), while statistical sig-
nificance (p < 0.05) was observed with maximum ∆P in
the four patient groups. No statistical difference was ob-
served for maximum ∆P in the healthy adult group for
Spiromax versus Turbuhaler. Distributions of individual
patient values for PIF, maximum ∆P and IV are depicted
in Figure 3. Pre-training, there were trends towards
Table 1 Summary of baseline characteristics and demographic data
Age (yrs) Height (cm) Weight (kg) Sex (F/M) PEFR (L/min) FEV1 (% predicted)
Mean (SD) Mean (SD) Mean (SD) N (%) Mean (SD) Mean % (SD)
Children with asthma (age 6–11; n = 23)
8.57 (2.00) 134.26 (18.25) 37.08 (13.64) F 9 (39.13) 182.74 (88.01) Not applicable
M 14 (60.87)
Adolescents with asthma (age 12–17; n = 27)
14.52 (1.55) 160.54 (7.63) 57.73 (12.17) F 14 (51.85) 310.07 (104.36) 64.63 (15.89)
M 13 (48.15)
Adults with asthma (age 18–45; n = 50)
34.74 (7.69) 168.06 (4.92) 75.48 (10.49) F 29 (58.00) 329.48 (101.51) 69.28 (16.63)
M 21 (42.00)
Adults with COPD (age > 50; n = 50)
66.82 (7.98) 168.74 (6.94) 78.09 (13.62) F 28 (56.00) 216.48 (93.25) 51.88 (21.90)
M 22 (44.00)
Healthy volunteers (age 18–45; n = 50)
32.62 (7.34) 171.20 (7.86) 73.82 (14.07) F 29 (58.00) 479.30 (127.58) 95.76 (14.31)
M 21 (42.00)
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slightly higher inspiratory ACC with Spiromax, with sta-
tistically significant differences in the COPD and healthy
adult groups (Table 2). Figure 3a shows that post-PIL
training, one adult with asthma and one COPD patient
inhaled <30 L/min with Spiromax and that one adult
with asthma and five patients with COPD inhaled
<30 L/min with the Turbuhaler. IV was also significantly
higher with Spiromax versus Turbuhaler in all study
groups.
Mean time to PIF was generally similar for the two de-
vices, ranging between 0.61 and 1.02 seconds across the
five study groups with Spiromax and between 0.79 and
1.19 seconds with Turbuhaler (data not shown). The
only group with a significant difference in time to PIF
was COPD patients, where it was significantly shorter
with Spiromax (0.68 vs 0.96 seconds, p = 0.0135). In each
study group, Ti was similar with both devices; the range
of mean values across the five study groups was 1.81–
2.94 seconds with the Spiromax device and 1.94–
3.02 seconds with Turbuhaler.
Effects of enhanced training
Enhanced training, when compared to standard PIL
training, significantly improved PIF, ACC, maximum ∆P
and IV (p < 0.05) in all study groups and with both in-
halers. Percentage improvements following enhanced
training were slightly larger with Turbuhaler than with
Spiromax (Table 3). With both devices, the parameter
with the highest percentage improvements in response
to enhanced training was ACC (Table 3). IV was the par-
ameter with the smallest percentage improvements.
After enhanced training, PIF remained significantly
higher with Spiromax versus Turbuhaler in all study
groups (p < 0.01; Table 3). Numerically or significantly
higher values with Spiromax versus Turbuhaler were
also observed for maximum ∆P, ACC and IV after en-
hanced training, with the exception of maximum ∆P in
COPD patients (Table 3). Time to PIF was shorter with
both devices after enhanced training, with study group
mean values ranging between 0.48 and 0.56 seconds with
Spiromax, and between 0.43 and 0.56 seconds with Tur-
buhaler. There were no significant post-training differ-
ences between the devices in time to PIF for any of the
study groups. Slight reductions were apparent in Ti
post-training, but mean values remained similar with
both devices.
Discussion
This study shows that most patients, regardless of age or
underlying disease severity, can achieve satisfactory in-
halation manoeuvre parameters through empty versions
of the Spiromax and Turbuhaler dry powder inhalers.
Enhanced training was useful to improve the inhalation
characteristics of those patients with peak inhalation
flows <30 L/min, especially COPD patients using the
Turbuhaler. The increases in response to enhanced













69.5‡ 67.9‡ 74.4‡ 57.5‡ 85.0‡
(17.2) (15.1) (18.1) (21.0) (13.6)
Max ΔP, kPa
5.0† 4.7* 5.7* 3.7† 7.3
(2.4) (2.2) (2.6) (2.7) (2.3)
ACC, kPa/s
13.6 12.1 15.6 11.0* 15.9*
(11.8) (8.8) (15.7) (12.8) (13.5)
Inhalation volume, L
1.50† 2.03† 2.39† 1.82† 2.98*
(0.6) (0.81) (1.03) (0.88) (1.02)
Turbuhaler
PIF, L/min
58.5 57.8 65.4 50.1 78.0
(14.7) (13.4) (17.5) (16.2) (11.8)
Max ΔP, kPa
3.9 3.9 5.1 3.1 7.0
(2.0) (1.8) (2.6) (2.0) (2.1)
ACC, kPa/s
10.2 11.4 13.0 8.4 12.8
(7.7) (7.2) (12.1) (9.5) (9.6)
Inhalation volume, L
1.25 1.68 2.13 1.58 2.80
(0.57) (0.74) (1.01) (0.69) (0.92)
Data shown are mean (standard deviation). *p < 0.05 vs Turbuhaler; †p < 0.01 vs Turbuhaler; ‡p ≤ 0.0001 vs Turbuhaler.

























































































































Figure 3 Individual peak inspiratory flow rates (A), maximum pressure change (ΔP) (B) and inhalation volume (C) before enhanced training. In
graph (A), the horizontal dotted line represents 30 L/min (minimal flow for adequate drug delivery).
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training highlight that there is room for improvement
and that training patients to use these devices can be
valuable. Although better inhalation characteristics were
achieved when inhaling through the empty Spiromax, it
is doubtful that this would translate into clinical differ-
ences between the devices since equivalence between
them has been shown among highly trained patients
[18]. PIF values were lower among the COPD patients
and the young asthma patients than among the adults
with asthma, and the healthy volunteers achieved the
highest PIF; these results were as expected [12].
There were statistically significant differences in key
parameters (PIF, maximum ∆P and ACC) between the
Spiromax and Turbuhaler, with greater improvements
overall typically seen in the Spiromax group. The excep-
tion was the higher maximum ∆P value achieved by the
Turbuhaler group, limited to COPD patients after en-
hanced training. This result must be considered in the
context that (1) after enhanced training, all COPD patients
in both groups achieved the minimal flow (30 L/min) re-
quired for adequate drug delivery and (2) prior to en-
hanced training, one COPD patient using Spiromax, as
opposed to five COPD patients using Turbuhaler, did not
achieve the minimal required flow rate. It may be argued
that these results are more reflective of clinical practice
than the finding that no patients failed to reach the
30 L/min threshold after enhanced training. The reason
for this is that few patients in clinical practice are likely to
receive training that is comparative to the enhanced train-
ing of this study. Also, several studies have highlighted
poor inhalation technique with DPIs in clinical practice
[25,26]. Usually, differences in flow characteristics be-
tween DPIs are related, at least in part, to different airflow
resistance [27]. However, the present results show the re-
verse. Since the patients likely used similar inspiratory ef-
fort with both devices, it would be expected that values
for ∆P and PIF would be higher for Turbuhaler because of
the higher resistance of this device. However these values
were slightly higher for Spiromax and suggest that add-
itional factors can influence the inhalation characteristics
of an inhalation manoeuvre.
Consistent with previous studies [11-13] enhanced
training produced significant improvement in the inhal-
ation parameters of individuals using both devices. Per-
centage increases in response to training were generally
larger with Turbuhaler than Spiromax. Comparison be-
tween the two devices of the effects of enhanced training
was consistent across the study groups: asthma patients
of different ages, COPD patients and healthy adults.
Smaller post enhanced training improvements with the
Spiromax device may reflect increased ease of use or
concordance during use and so the scope for improve-
ment is reduced if patients have good technique from
the outset. This notion is strengthened by the fact that a
proportion of patients in the present study were already
users of the Turbuhaler device, since pre-existing












PIF ± SD, L/min 77.99 ± 17.64† 83.87 ± 15.12‡ 85.45 ± 14.60‡ 68.08 ± 18.48‡ 98.68 ± 9.25‡
(Change ± SD, %) (14.18 ± 22.51) (26.34 ± 22.83) (19.31 ± 26.65) (25.27 ± 33.36) (18.93 ± 22.39)
Max ΔP ± SD, kPa 6.25 ± 2.64 7.11 ± 2.50* 7.36 ± 2.33† 3.94 ± 2.09 9.62 ± 1.66
(Change ± SD, %) (35.24 ± 59.55) (64.64 ± 60.13) (49.30 ± 74.81) (35.94 ± 81.15) (46.36 ± 58.85)
ACC ± SD, kPa/s 19.10 ± 14.63 26.72 ± 18.42 30.02 ± 25.30* 18.79 ± 17.07* 32.21 ± 17.19
(Change ± SD, %) (102.11 ± 171.24) (189.28 ± 234.48) (247.72 ± 482.94) (152.83 ± 233.91) (212.09 ± 284.44)
Inhalation volume ± SD, L 1.58 ± 0.60† 2.13 ± 0.67† 2.38 ± 1.12† 1.90 ± 0.90† 3.07 ± 1.05†
(Change ± SD, %) (14.68 ± 42.03) (10.09 ± 21.40) (1.25 ± 26.19) (14.73 ± 59.64) (6.41 ± 27.99)
Turbuhaler
PIF ± SD, L/min 69.46 ± 16.18 74.31 ± 12.94 76.73 ± 15.01 60.09 ± 16.95 90.36 ± 11.00
(Change ± SD, %) (20.03 ± 17.51) (32.68 ± 27.56) (22.17 ± 28.32) (24.06 ± 25.56) (18.16 ± 21.92)
Max ΔP ± SD, kPa 5.70 ± 2.53 6.38 ± 2.21 6.86 ± 2.51 4.37 ± 2.44§ 9.30 ± 2.09
(Change ± SD, %) (50.99 ± 40.47) (83.35 ± 82.04) (57.12 ± 89.53) (60.30 ± 73.15) (44.33 ± 56.21)
ACC ± SD, kPa/s 19.76 ± 12.37 23.58 ± 12.52 25.96 ± 20.29 15.72 ± 13.98 30.12 ± 14.34
(Change ± SD, %) (214.36 ± 295.99) (237.34 ± 365.66) (188.77 ± 271.47) (254.32 ± 426.12) (275.05 ± 389.83)
Inhalation volume ± SD, L 1.29 ± 0.53 1.77 ± 0.56 2.11 ± 0.90 1.66 ± 0.71 2.79 ± 0.96
(Change ± SD, %) (9.58 ± 31.29) (15.52 ± 30.85) (5.88 ± 34.35) (11.26 ± 40.03) (0.69 ± 19.91)
Data shown are mean ± standard deviation *p < 0.05 vs Turbuhaler; †p < 0.01 vs Turbuhaler; ‡p < 0.0001 vs Turbuhaler; §p < 0.01 vs Spiromax.
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expertise in using the Turbuhaler should in theory re-
duce the scope for improvement with this device. The
greatest improvements were in the acceleration rate
(with a faster time to the PIF), highlighting the import-
ance of training patients to inhale as fast as they can
from the start to ensure better de-aggregation of the
dose [7]. An understanding of the time taken to device
mastery (absence of critical errors) and maintenance of
device mastery with Spiromax and Turbuhaler, and the
identification of long-term real-life use of these two de-
vices in a population of adults with asthma, await further
study [28].
In addition to possible ‘increased ease of use’ or re-
duced need for training with Spiromax, patients may be
more familiar with the ‘look’ of the Spiromax inhaler
compared with the Turbuhaler because Spiromax has
contours similar to those of an MDI (DuoResp® Spiro-
max PIL). The majority of patients with asthma (at least
80%) or COPD (approximately 60%) were using an MDI
(for salbutamol) at the start of the study, compared with
30.4–51.9% who were using the Turbuhaler. However,
whether this contributed to the significant differences
seen between the devices (favouring Spiromax) is beyond
the scope of the current study. Furthermore, this finding
does not account for the significant differences between
the devices seen in the healthy adult group. Neither pa-
tient preference nor opinion (such as familiarity) of the
devices were assessed at any point during the study. The
evaluation of patient device preference (Turbuhaler and
Spiromax) awaits further study.
An important limitation of this study is the open-label
design, with training provided by a highly trained re-
searcher who also made the inhalation manoeuvre mea-
surements. This may have introduced the potential for
bias – there is a possibility that study participants would
use a device they recognise slightly differently from a
new device with which they are unfamiliar. Completion
of the study at one clinic visit is another drawback in re-
lation to applicability of the results because, in clinical
practice, inhalers are used in a variety of different envi-
ronments over long periods of time. It would be useful
to investigate whether the improvements resulting from
enhanced training would be maintained over time dur-
ing routine use. It is also yet to be established how flow
and pressure profiles might differ with empty devices (as
used here) versus those administrating a drug dose.
Study devices were otherwise unaltered, however, and
resistance measurements were not affected by the ab-
sence of drug and powder vehicle. An additional limita-
tion is the lack of information regarding drug delivery or
clinical effect; given the current study design, a robust
approach to clinical endpoints was not feasible, but the
data suggest that comparisons involving clinical end-
points should be of interest.
Conclusions
In conclusion, numerically or significantly higher pre-
training inhalation flow-related values were noted for
empty Spiromax versus empty Turbuhaler, with PIF re-
sults showing the largest differences. Airflow resistance
is slightly higher with Turbuhaler than with Spiromax,
although it may be considered as broadly similar in the
two devices. Although resistance has a major influence
on inhalation characteristics, there might be other hu-
man factors in real-world use. After enhanced training,
the flow-related differences persisted, but increased flow
rates were achieved with both devices to the point that
the minimal flow required for adequate drug delivery
was reached by all patients, including those who inhaled
<30 L/min before enhanced training (Spiromax: one
adult asthma patient and one COPD patient; Turbuha-
ler: one adult asthma patient and 5 COPD patients).
These results suggest that PIL training is effective for
Spiromax and Turbuhaler users, and enhanced training
may benefit selected patients with impairment in gener-
ating inspiratory force. The acceleration improvements
with a faster time to PIF highlight the importance of en-
couraging patients to inhale as fast as they can from the
start of the inhalation manoeuvre.
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